Literature DB >> 23834814

Anterior gradient 2: a novel sensitive tumor marker for metastatic oral cancer.

Yi-Ting Chen1, Chung-Liang Ho, Po-Ku Chen, Yuh-Ling Chen, Chuan-Fa Chang.   

Abstract

The prevention of oral squamous cell carcinoma metastasis to improve overall patient survival has provided the rationale for biomarker development. We used the Transwell invasion assay to isolate a highly metastatic subpopulation, HSC-3-5 cells, with almost the same genetic background as HSC-3 cells but a higher metastatic capacity accompanied by cytoskeletal rearrangements and mesenchymal transformation. HSC-3-5 cells also showed tumorigenic and metastatic characteristics in vivo. In addition, Anterior gradient 2 (agr2), a pro-oncogenic signaling intermediate, was identified from gene expression profiling, and overexpression of AGR2 showed a positive correlation with oral tumor metastasis. Taken together, our data suggest that AGR2 may be a novel sensitive biomarker for metastatic oral cancer.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anterior gradient 2; HSC-3; Metastasis; Oral squamous cell carcinoma

Mesh:

Substances:

Year:  2013        PMID: 23834814     DOI: 10.1016/j.canlet.2013.06.025

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Epidermal growth factor receptor (EGFR) signaling requires a specific endoplasmic reticulum thioredoxin for the post-translational control of receptor presentation to the cell surface.

Authors:  Aiwen Dong; Dariusz Wodziak; Anson W Lowe
Journal:  J Biol Chem       Date:  2015-02-09       Impact factor: 5.157

2.  Hesperetin on Cell Surface Glycoconjugates Abnormalities and Immunohistochemical Staining with Cytokeratin in 7,12 Dimethylbenz(a)anthracene Induced Hamster Buccal Pouch Carcinogenesis.

Authors:  Sukumar Babukumar; Veerasamy Vinothkumar; Periyannan Velu; Duraisamy Ramachandhiran
Journal:  Indian J Clin Biochem       Date:  2017-11-04

3.  AGR2 promotes the proliferation, migration and regulates epithelial-mesenchymal transition in salivary adenoid cystic carcinoma.

Authors:  Si-Rui Ma; Liang Mao; Wei-Wei Deng; Yi-Cun Li; Lin-Lin Bu; Guang-Tao Yu; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

4.  Expression of Cancer Stem Cell Biomarkers in Human Head and Neck Carcinomas: a Systematic Review.

Authors:  Raissa Borges Curtarelli; Jussara Maria Gonçalves; Luciane Geanini Pena Dos Santos; Maria Gorete Savi; Jacques Eduardo Nör; Luis André Mendonça Mezzomo; Mabel Mariela Rodríguez Cordeiro
Journal:  Stem Cell Rev Rep       Date:  2018-12       Impact factor: 5.739

5.  Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients.

Authors:  Qian Zhang; Xiao-Qing Wang; Jie Wang; Shu-Jian Cui; Xiao-Min Lou; Bing Yan; Jie Qiao; Ying-Hua Jiang; Li-Jun Zhang; Peng-Yuan Yang; Feng Liu
Journal:  Oncotarget       Date:  2015-06-20

6.  Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.

Authors:  Si-Rui Ma; Wei-Ming Wang; Cong-Fa Huang; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Oncotarget       Date:  2015-04-20

7.  Plac1 Remodels the Tumor Immune Evasion Microenvironment and Predicts Therapeutic Response in Head and Neck Squamous Cell Carcinoma.

Authors:  Xiaoyan Meng; Zhonglong Liu; Lingfang Zhang; Yue He
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

8.  High expression of AGR2 in lung cancer is predictive of poor survival.

Authors:  Mohammed Alavi; Vei Mah; Erin L Maresh; Lora Bagryanova; Steve Horvath; David Chia; Lee Goodglick; Alvin Y Liu
Journal:  BMC Cancer       Date:  2015-10-06       Impact factor: 4.430

Review 9.  Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?

Authors:  Robert S O'Neill; Alina Stoita
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.